(0.32%) 5 116.17 points
(0.38%) 38 386 points
(0.35%) 15 983 points
(-1.35%) $82.72
(6.40%) $2.05
(0.00%) $2 347.30
(-0.27%) $27.46
(4.10%) $959.95
(-0.21%) $0.933
(-0.35%) $10.99
(-0.55%) $0.796
(1.66%) $93.40
@ $0.910
发出时间: 14 Feb 2024 @ 03:52
回报率: -23.48%
上一信号: Feb 13 - 02:31
上一信号:
回报率: 3.99 %
Live Chart Being Loaded With Signals
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States...
Stats | |
---|---|
今日成交量 | 1.25M |
平均成交量 | 1.40M |
市值 | 157.52M |
EPS | $0 ( 2024-03-15 ) |
下一个收益日期 | ( $-0.190 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.590 |
ATR14 | $0.00200 (0.29%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-27 | Christian Waage | Sell | 6 430 | Common Stock |
2024-03-27 | Giraudo Bryan | Sell | 6 430 | Common Stock |
2024-03-27 | Hasnain Faheem | Sell | 23 172 | Common Stock |
2024-03-18 | Aranda Richard | Sell | 4 018 | Common Stock |
2024-03-18 | Peterson Caryn | Sell | 4 018 | Common Stock |
INSIDER POWER |
---|
76.16 |
Last 96 transactions |
Buy: 11 435 031 | Sell: 1 983 654 |
音量 相关性
Gossamer Bio Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Gossamer Bio Inc 相关性 - 货币/商品
Gossamer Bio Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-4.39M (0.00 %) |
EPS: | $-1.180 |
FY | 2023 |
营收: | $0 |
毛利润: | $-4.39M (0.00 %) |
EPS: | $-1.180 |
FY | 2022 |
营收: | $0 |
毛利润: | $-4.43M (0.00 %) |
EPS: | $-2.84 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.13 |
Financial Reports:
No articles found.
Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。